FDA approves first pill to prevent recurrent C. difficile infections
The Food and Drug Administration approved the first fecal microbiota product taken orally to prevent recurrent C. difficile infection.
“Today’s approval provides patients and healthcare providers a new way to help prevent recurrent C. difficile infection,” said Peter Marks, M.D., director of the FDA’s Center for Biologics Evaluation and Research. “The availability of a fecal microbiota product that can be taken orally is a significant step forward in advancing patient care and accessibility for individuals who have experienced this disease that can be potentially life-threatening.”
Related News Articles
Headline
There have been 1,168 confirmed cases of measles across 33 states as of June 6 this year, according to the latest data from the Centers for Disease Control and…
Headline
A JAMA study published June 3 found that of 2,237 counties across the U.S., 78% reported declines in vaccination rates for measles, mumps and rubella from 2019…
Headline
There have been 1,024 confirmed cases of measles across the U.S. so far in 2025, according to the latest data from the Centers for Disease Control and…
Headline
There have been 1,001 confirmed cases of measles across the U.S. so far in 2025, according to the latest data from the Centers for Disease Control and…
Headline
Though seasonal flu activity is low or minimal across the country, 216 pediatric deaths associated with seasonal influenza virus infection have been tallied so…
Headline
The U.S. has had 935 confirmed cases of measles so far this year, according to the latest data from the Centers for Disease Control and Prevention. Cases have…